Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis
Núria Guañabens, Anna Monegal, Dacia Cerdá, África Muxí, Laia Gifre, Pilar Peris, Albert Parés – 17 May 2013 – Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once‐weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2‐year study in 42 postmenopausal women with PBC and osteoporosis.